emerg
pathogen
ebolavirus
ebov
avian
influenza
virus
sever
acut
respiratori
syndrom
sar
viru
middleeast
coronaviru
mer
chikungunya
viru
chikv
dengu
viru
pose
public
health
challeng
demand
research
govern
work
togeth
assess
pandem
potenti
plan
mitig
strategi
five
speci
ebov
belong
filovirida
includ
zair
ebolaviru
ebovz
bundibugyo
ebolaviru
ebovb
reston
ebolaviru
sudan
ebolaviru
ebov
tai
forest
ebolaviru
ebovz
ebov
respons
major
outbreak
highli
pathogen
haemorrhag
fever
caus
high
fatal
rate
past
outbreak
limit
size
affect
local
popul
howev
strain
ebovz
caus
agent
current
outbreak
began
late
sinc
becom
unpreced
devast
epidem
result
suspect
case
confirm
case
fatal
rate
around
afflict
west
african
countri
http
langen
http
wwwwhointcsrdiseaseebolasituationreportsen
toward
end
trend
case
number
revers
liberia
epidem
slow
sierra
leon
guinea
viru
continu
transit
new
geograph
area
epidem
trigger
signific
global
health
respons
reli
primari
hygien
contain
measur
prove
success
limit
spread
viru
previou
outbreak
given
scale
outbreak
fear
tradit
contain
measur
may
fail
prevent
global
spread
sever
vaccin
fasttrack
phase
clinic
trial
although
even
prove
efficaci
limit
suppli
suffici
quantiti
vaccin
hinder
use
current
situat
diseas
treatment
patient
suffer
haemorrhag
fever
reli
clinic
manag
symptom
http
wwwcdcgovvhfebolatreat
hand
patient
outbreak
receiv
experiment
therapi
zmapp
tkmebola
brincidofovir
favipiravir
http
altern
antibodi
treatment
transfus
therapi
use
blood
plasma
ebola
viru
survivor
approv
although
issu
safeti
lack
resourc
method
limit
suitabl
west
africa
today
approv
wide
avail
therapeut
ebov
mani
emerg
viral
diseas
focu
turn
possibl
repurpos
drug
alreadi
licens
use
ema
fda
sever
clinic
approv
drug
identifi
research
includ
amiodaron
one
sever
cation
amphiphil
found
inhibit
filoviru
entri
current
triall
sierra
leon
howev
reserv
express
complic
could
caus
side
effect
drug
ebov
patient
antimalari
drug
chloroquin
cq
also
shown
inhibit
ebov
entri
protect
mice
ebov
infect
previous
highlight
possibl
drug
treat
ebov
infect
possibl
difficulti
may
aris
use
repurpos
drug
includ
unforeseen
interact
virusdrug
host
caus
exacerb
diseas
therefor
import
tri
understand
mechan
viru
inhibit
drug
end
reexamin
antivir
properti
cq
show
inhibit
phdepend
endosom
entri
pseudotyp
viru
pv
bear
ebov
glycoprotein
way
potent
specif
vacuolaratpas
vatpas
inhibitor
bafilyomycin
nonmed
laboratori
compound
also
show
licens
wide
use
proton
pump
inhibitor
ppi
treatment
gastric
acid
reflux
omeprazol
om
esomeprazol
esom
inhibit
pv
ebov
entri
like
offtarget
inhibitori
activ
endosom
vatpas
human
embryon
kidney
atcc
human
lung
adenocarcinoma
epitheli
cell
attc
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fetal
calf
serum
fc
biosera
penicillinstreptomycin
ps
invitrogen
cell
line
maintain
co
atmospher
chloroquin
diphosph
salt
cq
bafilomycin
streptomyc
griseu
omeprazol
om
esomeprazol
magnesium
hydrat
esom
sigma
resuspend
per
manufactur
instruct
aliquot
store
cq
prepar
steril
dh
om
esom
prepar
steril
dmso
sigma
bundibugyo
ebolaviru
ebovb
envelop
glycoprotein
gp
code
sequenc
synthesis
bio
basic
inc
ha
glycoprotein
avian
influenza
amplifi
ha
plasmid
revers
genet
system
subclon
pcagg
express
vector
express
vector
contain
envelop
glycoprotein
zair
ebolaviru
mayinga
ebovz
marburg
viru
lake
victoria
isol
marv
gibbon
ape
leukemia
viru
galv
modifi
contain
transmembran
domain
amphotrop
murin
leukemia
viru
amlv
envelop
glycoprotein
describ
previous
renilla
luciferas
gene
subclon
pcagg
express
vector
minigenom
report
describ
previous
gener
lentivir
pseudotyp
virus
base
method
detail
previous
briefli
cell
seed
tissu
cultur
plate
thermo
scientif
hiv
gagpol
plasmid
firefli
luciferas
report
construct
pcsflw
transfect
togeth
either
influenza
ha
galv
ebov
marburg
gp
express
construct
ratio
core
report
envelop
use
transfect
reagent
promega
h
posttransfect
cell
wash
fresh
media
appli
gener
pv
exogen
recombin
neuraminidas
clostridium
perfringen
sigmaaldrich
also
ad
h
transfect
effect
egress
produc
cell
pv
supernat
harvest
h
posttransfect
pass
pore
filter
ebov
pv
aliquot
store
remain
pv
store
cell
plate
transfect
renilla
luciferas
express
plasmid
use
lipofectamin
accord
manufactur
instruct
life
cq
om
esom
serial
dilut
whitebottom
plate
thermo
scientif
give
final
describ
concentr
transfect
cell
trypsinis
cell
ad
well
cell
transduc
rlu
pv
per
well
estim
raw
rlu
valu
previous
infect
cell
equal
volum
per
well
h
later
supernat
remov
cell
lyse
passiv
lysi
buffer
promega
firefli
renilla
luciferas
activ
measur
use
fluostar
omega
plate
reader
bmg
labtech
dual
luciferas
assay
system
promega
cell
pretreat
drug
h
ph
sensit
lysotrack
red
life
ad
media
well
growth
condit
cell
analyz
fluoresc
use
axiovert
confoc
laser
cfl
microscop
axiocam
mrc
camera
carl
zeiss
pv
transduct
rlu
normalis
renilla
valu
correspond
well
percent
infect
drug
dilut
calcul
compar
untreat
cell
twoway
anova
bonferroni
multipl
comparison
test
untreat
treat
mean
valu
perform
measur
statist
signific
differ
ic
valu
calcul
use
nonlinear
regress
analysi
log
inhibitor
vs
normalis
respons
manipul
data
perform
graphpad
prism
graphpad
softwar
envelop
glycoprotein
sever
emerg
virus
high
pathogen
pandem
potenti
use
creat
lentivir
base
pseudotyp
particl
previous
describ
pv
gener
bear
envelop
glycoprotein
zair
ebolaviru
mayinga
strain
ebovz
bundibugyo
ebolaviru
ebovb
marburg
lake
victoria
isol
viru
marv
ha
highli
pathogen
avian
influenza
viru
gibbon
ape
leukaemia
viru
galv
galv
pv
includ
galv
viru
requir
acidif
endosom
entri
cell
pv
gener
shown
transduc
cell
firefli
luciferas
express
packag
report
gene
measur
mock
infect
cell
nontransduc
cell
dataset
order
assess
abil
cq
om
esom
inhibit
pv
entri
drug
serial
dilut
triplic
white
bottom
plate
next
cell
transfect
hour
previous
renilla
luciferas
express
plasmid
allow
monitor
cell
viabil
ad
well
appropri
dilut
pv
ad
dilut
includ
nodrug
control
hour
incub
supernat
remov
firefli
renilla
luciferas
rlu
record
use
dual
luciferas
assay
system
promega
pv
rlu
normalis
correspond
renilla
valu
reduc
edg
effect
observ
plate
control
toxic
drug
appear
reduc
express
renilla
highest
concentr
suggest
cellular
toxic
dataset
visibl
cytopath
effect
observ
cell
treat
cq
om
esom
concentr
use
figur
cq
reduc
ebovz
ebovb
marv
entri
dose
depend
manner
figur
b
ic
valu
nm
rang
ebovz
ebovb
marv
inhibit
entri
statist
signific
concentr
compar
untreat
control
tabl
cq
inhibit
ebovz
ebovb
marv
ic
respect
inhibit
statist
signific
tabl
contrast
galv
entri
augment
cq
untreat
cell
maximum
respect
om
esom
reduc
entri
pv
test
galv
pv
least
affect
figur
inhibit
entri
ebovz
ebovb
marv
pv
esom
signific
galv
pv
significantli
inhibit
dose
figur
tabl
cq
known
endosom
acidif
inhibitor
potent
specif
vatpas
inhibitor
cq
licens
lysotrop
agent
effect
om
esom
endosom
acidif
also
previous
report
confirm
endosom
ph
affect
dose
use
cell
treat
drug
hour
appli
lysotrack
red
lifetechnolog
cell
chosen
cell
poorli
imag
due
morpholog
lysotrack
probe
specif
fluoresc
acid
organel
fluoresc
decreas
cell
treat
cq
dose
depend
manner
unaffect
cell
treat
vehicl
alon
figur
om
esom
appear
decreas
fluoresc
therefor
increas
endosom
ph
concentr
higher
requir
inhibit
pv
entri
moreov
cellular
toxic
observ
concentr
hour
attach
cell
virus
requir
mechan
fusion
deliv
viral
genom
prevent
action
fusion
inhibitor
success
approach
hiv
antivir
therapi
unlik
hiv
ebov
mani
virus
depend
natur
low
ph
acid
endosom
activ
trigger
fusion
envelop
glycoprotein
instanc
fusion
inhibitor
could
target
host
cell
machineri
prevent
acidif
endosom
work
inhibit
viru
entri
sever
differ
virus
reiter
cell
entri
pv
repres
ebov
marv
inhibit
increas
endosom
ph
use
cq
figur
correl
abil
prevent
acidif
intracellular
organel
figur
cq
shown
antivir
activ
sever
virus
vitro
includ
ebov
influenza
nipah
hendra
dengu
chikv
disappointingli
antivir
activ
alway
translat
efficaci
vivo
model
clinic
trial
although
cq
effect
mous
model
ebov
variabl
vivo
result
may
depend
studi
design
strain
viru
use
one
studi
treat
mice
protect
influenza
infect
treatment
relat
compound
saliph
protect
even
though
drug
potent
vitro
inhibit
endosom
acidif
target
inhibit
ebov
justifi
knowledg
filovirus
depend
low
ph
two
separ
step
entri
pathway
fusion
g
protein
trigger
low
ph
cleavag
fusogen
form
carri
endosom
enzym
cathepsin
b
l
whose
activ
also
ph
depend
argu
g
protein
cleavag
cathepsin
less
essenti
previous
thought
ebov
speci
zair
togeth
close
relat
marv
requir
cathepsin
cleavag
entri
nonetheless
entri
marv
pv
still
inhibit
assay
suggest
inhibit
fusion
alon
suffici
recent
use
comput
model
ekin
et
al
suggest
antiebov
mechan
cq
may
bind
protein
ebov
drug
activ
sever
step
replic
cycl
may
effect
vivo
may
even
less
like
viru
could
mutat
escap
inhibit
first
surpris
cq
actual
increas
entri
galv
pv
figur
howev
effect
note
retrovirus
includ
amlv
account
inhibitori
effect
cq
autophagi
pathway
cq
prevent
degrad
phagosom
contain
viru
particl
prevent
otherwis
degrad
cq
use
mani
year
antimalari
drug
although
effect
part
central
america
caribbean
due
accumul
drug
resist
plasmodium
parasit
interestingli
compound
belong
omeprazol
famili
also
describ
antimalari
properti
vitro
possibl
via
report
abil
target
vatpas
plasma
membran
plasmodium
parasit
soon
discoveri
om
found
also
inhibit
intracellular
vatpas
concentr
oppos
licens
target
gastric
hkatpas
effect
much
lower
concentr
inde
plethora
public
indic
use
om
esom
cancer
therapi
mean
inhibit
characterist
acid
intracellular
environ
thu
permit
sensit
cytotox
therapi
role
om
esom
also
note
suppress
bone
resorpt
anoth
physiolog
process
depend
ph
given
volum
research
suggest
target
effect
depend
abil
affect
intracellular
ph
hypothesis
drug
would
like
cq
inhibit
ebov
marv
influenza
viru
ph
depend
entri
use
galv
control
sinc
entri
reportedli
independ
ph
inde
ebov
marv
inhibit
lower
dose
om
esom
galv
figur
tabl
galv
entri
also
inhibit
highest
concentr
exclud
due
toxic
effect
measur
renilla
control
employ
observ
close
correl
drug
dose
mediat
inhibit
ebov
influenza
pv
entri
increas
ph
intracellular
vesicl
om
esom
cq
bafa
figur
figur
recent
report
om
esom
alter
localis
vatpas
cell
well
ph
intracellular
vesicl
may
explain
abil
inhibit
pv
entri
potent
ph
chang
observ
would
suggest
inhibit
influenza
viru
entri
cell
mean
inhibit
acidif
endosom
known
decad
although
current
antivir
influenza
licens
basi
epidemiolog
evid
popul
studi
suggest
om
could
exert
protect
effect
influenzalikeil
studi
suggest
dose
requir
potent
inhibit
might
difficult
achiev
without
signific
toxic
despit
drug
readili
avail
even
without
prescript
countri
licens
dose
would
gener
plasma
concentr
reportedli
esom
fall
short
ic
calcul
studi
although
higher
dose
use
clinic
therefor
seem
unlik
om
esom
would
suitabl
therapi
ebolaviru
infect
specif
design
vatpas
inhibitor
may
potenti
broad
act
antivir
sever
emerg
virus
futur
regard
cq
evid
suggest
promis
posit
use
ebolaviru
standard
adult
dose
achiev
plasma
concentr
close
ic
valu
ebov
pv
entri
protect
mous
model
previous
shown
dosag
use
repurpos
drug
treat
outbreak
emerg
diseas
must
sure
approach
caution
ebola
patient
sever
lifethreaten
diseas
would
import
ensur
side
effect
therapi
enhanc
diseas
progress
particularli
higher
dose
repurpos
drug
suggest
consid
hand
cq
taken
prophylact
tropic
set
mani
year
prevent
malaria
suggest
littl
addit
need
scale
product
new
agent
might
repres
use
adjunct
current
antivir
strategi
triall
west
africa
envisag
contact
ebov
case
cq
might
decreas
viral
load
establish
earli
day
viru
transmiss
work
vivo
model
includ
guinea
pig
primat
inform
dose
administr
regimen
figshar
inhibit
pseudotyp
viru
entri
exist
fdaapprov
drug
doi
http
